amifostine anhydrous has been researched along with methionine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Campomenosi, P; Frebourg, T; Fronza, G; Hainaut, P; Maurici, D; Monti, P; North, S | 1 |
1 review(s) available for amifostine anhydrous and methionine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for amifostine anhydrous and methionine
| Article | Year |
|---|---|
Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Topics: Amifostine; Amino Acid Substitution; Animals; Cloning, Molecular; Codon; Esophageal Neoplasms; Gene Expression Regulation; Humans; Mammals; Methionine; Models, Molecular; Mutagenesis, Site-Directed; Polyamines; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Conformation; Protein Structure, Secondary; Radiation-Protective Agents; Recombinant Proteins; Saccharomyces cerevisiae; Temperature; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Valine | 2001 |